Company intelligence / Profile preview

Cannenta

Melbourne, Victoria, Australiacannenta.com ↗

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

Developing a patented sugar-based angiogenesis factor (2-deoxy-D-ribose) that stimulates VEGF production to accelerate wound healing. As of 2021, was preparing for clinical trials.

Therapeutic areas: DermatologyEndocrinology
Modalities: Sugar-based angiogenesis factor
Industry: Biotech

Drug pipeline

2 assets

2-deoxy-D-ribose

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Working with established manufacturers to incorporate technology into suitable product carriers

Beyond the preview

Go deeper on Cannenta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cannenta.

Explore the full profile